In this study, we assessed the effects of HDM201 on B cell lines and ex vivo patient-derived primary CLL cells and compared these effects with those observed in TP53 mutant cells as well as on normal hematopoietic cells. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.